Shield Reports on H1 Business Update

23 Jul 2018

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, with an initial focus on addressing iron deficiency with its approved product, Feraccru®, today announces a business update following progress made in H1 2018.

Following the Company’s detailed analyses of the positive data from the placebo-controlled period of the AEGIS-CKD study, we completed a planned pre-NDA submission meeting with the FDA at which we presented the positive AEGIS-CKD study results together with a broader discussion regarding the Company’s intention to file an NDA for Feraccru in 2018.

You can read the full press release here.

Back to news

London, UK

16 Upper Woburn Place
London, WC1H 0AF

t+44 (0) 207 186 8500

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau

t+41 (0) 435 080 781

Berlin, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin

t+44 (0) 207 186 8500